IgG Immunoblot; IgG detected against:; IgM Immunoblot; IgM detected against:; Interpretation
Lyme Disease Antibody Immunoblot, Serum
Test
Method
Immunoblot Microarray
Method Description
The Viramed Biotech AG Borrelia B31 ViraChip IgM and IgG are protein microarray assays, and can be considered modified solid-phase enzyme linked immunosorbent assays (ELISAs). Highly purified antigens from the Borrelia burgdorferi B31 strain, including the 93 kD, 66 kD, 58 kD, 45 kD, 41 kD, 39 kD, 30 kD, 28 kD, 23 kD, and 18 kD proteins, are bound to the solid phase nitrocellulose membrane in triplicate. The positions of these antigen “spots” are well defined and are reliably identifiable using customized software. Each microarray also has “spots” for a negative control, serum controls, conjugate controls, and 6 calibrators. One microarray is fixed to the bottom of a well in a standard 96-well microtiter plate.
For each test to be performed, the diluted patient serum is added to each microarray (note: the B burgdoreri IgG and IgM microarrays are in separate wells). If specific antibodies recognizing a B burgdorferi antigen are present, they will bind to the specific antigens on the microarray. After incubation the microarray is washed to remove unbound antibodies. Alkaline-phosphatase antihuman IgG or antihuman IgM (conjugate) is then added to the well and incubated. If antibodies are present, the conjugate will bind to those respective antibodies, and after a washing step to remove unbound conjugate, substrate solution is added. If the antibody/conjugate complex is present, the substrate will undergo precipitation and color change. After an incubation period, the reaction is stopped and the presence of precipitated substrate is visualized at specific locations on the microarray. The presence of a colored precipitation at various locations on the microarray is an indirect measurement of B burgdorferi specific antibodies in the patient specimen. Visualized spots from the reaction are compared for intensity with the integrated calibrator controls for evaluation. (Package inserts: Borrelia B31 ViraChip IgM and Borrelia B31 ViraChip IgG, July 2016, VIRAMED Biotech AG, Planegg, Germany)
Platform
Viramed Biotech AG Borrelia B31 ViraChip IgM and IgG
Report Includes
Specimens
Serum
Clinical Utility
Aids in the diagnosis of systemic Lyme disease
Test Location
Mayo Clinical Labs, Minnesota USA
Test Version
7-Nov-2019
Specimen
Specimens
Serum
Sample Volume
0.75 mL
Minimum Volume
0.5 mL
Specimen Comment
Gel-separator tubes are acceptable.
Collection & Handling
Handling Information
Store and send cold or frozen.
Stability
Refrigerated | 14 days |
---|---|
Frozen | 30 days |
Rejection Criteria
Hemolysis | Gross |
---|---|
Lipemia | Gross |
Other | Grossly icteric |
Test Version
7-Nov-2019
Performance / Interpretation
Method
Immunoblot Microarray
Method Description
The Viramed Biotech AG Borrelia B31 ViraChip IgM and IgG are protein microarray assays, and can be considered modified solid-phase enzyme linked immunosorbent assays (ELISAs). Highly purified antigens from the Borrelia burgdorferi B31 strain, including the 93 kD, 66 kD, 58 kD, 45 kD, 41 kD, 39 kD, 30 kD, 28 kD, 23 kD, and 18 kD proteins, are bound to the solid phase nitrocellulose membrane in triplicate. The positions of these antigen “spots” are well defined and are reliably identifiable using customized software. Each microarray also has “spots” for a negative control, serum controls, conjugate controls, and 6 calibrators. One microarray is fixed to the bottom of a well in a standard 96-well microtiter plate.
For each test to be performed, the diluted patient serum is added to each microarray (note: the B burgdoreri IgG and IgM microarrays are in separate wells). If specific antibodies recognizing a B burgdorferi antigen are present, they will bind to the specific antigens on the microarray. After incubation the microarray is washed to remove unbound antibodies. Alkaline-phosphatase antihuman IgG or antihuman IgM (conjugate) is then added to the well and incubated. If antibodies are present, the conjugate will bind to those respective antibodies, and after a washing step to remove unbound conjugate, substrate solution is added. If the antibody/conjugate complex is present, the substrate will undergo precipitation and color change. After an incubation period, the reaction is stopped and the presence of precipitated substrate is visualized at specific locations on the microarray. The presence of a colored precipitation at various locations on the microarray is an indirect measurement of B burgdorferi specific antibodies in the patient specimen. Visualized spots from the reaction are compared for intensity with the integrated calibrator controls for evaluation. (Package inserts: Borrelia B31 ViraChip IgM and Borrelia B31 ViraChip IgG, July 2016, VIRAMED Biotech AG, Planegg, Germany)
Platform
Viramed Biotech AG Borrelia B31 ViraChip IgM and IgG
Turnaround Time
14 days
Results
Name | Units | Reference Range | Conversion Factor | |
---|---|---|---|---|
IgG Immunoblot |
|
|||
IgG Detected Against |
|
|||
IgM Immunoblot |
|
|||
IgM Detected Against |
|
|||
Interpretation |
Test Location
Mayo Clinical Labs, Minnesota USA
Test Version
7-Nov-2019
Interface / Setup
Test Version
7-Nov-2019